Quality of life is an important criterion for the efficiency of targeted therapy for metastatic skeletal involvement in breast cancer

Cover Page

Cite item

Full Text

Abstract

Assessment of quality of life is an important, valid, informative, and cost-effective procedure for evaluating the efficiency of treatment in patients with breast cancer metastasizing to the bone, receiving therapy with bone-modifying agents, including targeted therapy with denosumab. The administration of denosumab significantly improves quality of life in patients with breast cancer metastasizing to the bone, by maintaining their general status, reducing the intensity of pain syndrome, and prevents osseous complications: pathological fractures, spinal cord compression, hypercalcemia, as well as the need for radiotherapy or surgery for bone metastases.

About the authors

T. Yu. Semiglazova

N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburg

Author for correspondence.
Email: tsemiglazova@mail.ru
Russian Federation

V. V. Semiglazov

Acad. I.P. Pavlov Saint Petersburg State Medical University, Ministry of Health of Russia

Russian Federation

L. V. Filatova

N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburg

Russian Federation

P. V. Krivorotko

N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburg

Russian Federation

V. V. Kolarkova

N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburg

Russian Federation

V. F. Semiglazov

N.N. Petrov Oncology Research Institute, Ministry of Health of Russia, Saint Petersburg

Russian Federation

References

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 36991 от  21.07.2009.